Genflow Biosciences - GENFF STOCK NEWS

Genflow Biosciences PLC (GENFF) has reported a significant change in shareholding. Jonathan Mark Swann from Rickmansworth, UK, has increased his voting rights in the company from 5.03% to 6.01%, representing 21,025,000 voting rights. The threshold was crossed on January 10, 2025, and the company was notified on January 13, 2025.

The notification indicates this change resulted from an acquisition of voting rights, with all shares being held directly. No financial instruments or similar economic instruments were reported as part of this holding. The shareholder is not controlled by any natural person or legal entity and does not control any other undertaking holding interests in Genflow Biosciences.

Genflow Biosciences PLC has reported a significant change in shareholding, with Premier Miton Group plc crossing a notification threshold on January 9, 2025. The investment firm now holds 15,147,262 voting rights, representing 4.33142% of the company's total voting rights, down from their previous position of 9.15053%.

The change was due to an acquisition or disposal of financial instruments, as reported through a standard TR-1 form. The notification was formally submitted on January 10, 2025, with Premier Fund Managers , a controlled undertaking of Premier Miton Group plc, being the entity holding the voting rights.

Genflow Biosciences has reported key developments for 2024 in their aging-focused therapeutic programs. The company's MASH program (GF-1002) is advancing to pre-IND phase, partnering with Exothera SA for GMP manufacturing of clinical lots. For Werner Syndrome (GF-1003), they've developed proprietary liver organoids from human patient cells. The Dog Aging program (GF-1004) is initiating a six-month life extension clinical trial in collaboration with Syngene, expected to complete analysis by end of 2025.

Their Sarcopenia program (GF-1005) is progressing with myoblast progenitor studies in partnership with Université libre de Bruxelles, focusing on mitochondrial dysfunction. The company received support from the Belgian Government and has strengthened its research collaborations throughout the year.

Genflow, an emerging leader in longevity research, announced it has secured €4,026,525 in non-dilutive financial support from the Wallonia region for the development of its lead gene therapy, GF-1002, aimed at treating Metabolic Associated Steatohepatitis (MASH). The support includes a €1,218,349.44 non-reimbursable research grant covering 70% of research costs and a €2,808,175.92 recoverable advance, repayable upon commercialization, funding 55% of development costs. This funding is expected to cover three years of development, with the first installment to be received as working capital. This milestone will accelerate GF-1002's clinical progress, addressing a condition with treatment options. Dr. Eric Leire, CEO, expressed gratitude for the Wallonia region's support, emphasizing its validation of Genflow's innovative gene therapy work. Further updates on GF-1002's progress will be shared in due course.

Genflow Biosciences (LSE:GENF) released its half-year report for the period ending June 30, 2024. Key developments include progress in its longevity programs for MASH and Werner Syndrome, enhanced by the FDA's encouragement to proceed with pilot proof-of-concept studies using 3-D liver organoids from Werner patients. Additionally, Genflow initiated a feasibility study with Exothera S.A. for GMP-compliant production and is selecting CROs for a dog clinical trial of GF-1004.

The company received €777,281 in grants for collaborations on sarcopenia and exosome-mRNA projects and €350,000 from the Wallonia government. Financially, Genflow raised £715,000 in equity financing, bringing cash reserves to £1,139,859, despite higher administration expenses of £1,316,368. The period's operating loss was £524,259. The company remains debt-free and expects future funding to support its R&D activities.

Genflow Biosciences (LSE:GENF, OTCQB:GENFF), a leader in longevity research, announced that all resolutions at the Annual General Meeting (AGM) held on June 27, 2024, were approved.

Genflow Biosciences has announced significant strides in its pre-clinical efforts for the development of therapeutic solutions targeting age-related diseases. The company has initiated a feasibility study with Exothera S.A., a CDMO, to ensure GMP-compliant production of clinical lots. Genflow is also in the process of selecting CROs for its upcoming dog clinical trial of GF-1004. Additionally, the FDA has provided research guidance through INTERACT, advising Genflow to proceed with pilot proof-of-concept studies for GF-1002, aimed at treating Metabolic Associated Steatohepatitis (MASH). The FDA's feedback supports the continuation of toxicology and biodistribution studies, which are important for eventual clinical trials. This progress highlights Genflow's commitment to advancing its therapeutic pipeline.

Genflow Biosciences (LSE:GENF, OTCQB:GENFF), an emerging leader in longevity research, announced receiving €395,847, representing 50% of the Exofastrack research grant from the Government of Wallonia. This grant, a non-dilutive, non-reimbursable subsidy, will cover 80% of the expenses for a 3-year scientific program in collaboration with EXO Biologics. The program aims to develop exosome-based therapies targeting liver fibrosis (MASH) and Werner Syndrome. CEO Dr. Eric Leire expressed enthusiasm, emphasizing the potential for groundbreaking treatments in age-related disease prevention.

Genflow Biosciences, an emerging leader in longevity research, has announced its Annual General Meeting (AGM) scheduled for June 27, 2024, at 12 pm in London. The Notice of AGM and the 2024 Form of Proxy will soon be available on the company's website. Additionally, the company has published its Annual Report and Accounts for the year ending December 31, 2023, on the website.